SWKHL

SWK Holdings Corp. 10-K Summary: Fiscal Year Ended December 31, 2024

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2024. SWK Holdings Corporation operates two reportable segments: Finance Receivables, which provides customized financing solutions (royalties and debt) to life science companies, and Pharmaceutical Development, which provides clinical development and manufacturing services. The Company is headquartered in Dallas, Texas, and is classified as a smaller reporting company.

Key Financial Metrics

Note: Total Debt includes $6.2 million on the revolving credit facility and $31.4 million in Senior Notes (net of issuance costs).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $7.2 million (19%) driven by a $4.8 million increase in Finance Receivables revenue (due to new loan funding) and a $2.4 million increase in Pharmaceutical Development revenue.
• Provision for Credit Losses: Increased significantly to $12.8 million from $1.9 million in 2023. This was primarily due to an $8.1 million impairment on the Trio loan and a $2.2 million impairment on the Exeevo loan.
• Impairments: Recognized a $5.8 million loss on impairment of intangible assets related to the Cara Therapeutics license agreement, which was deemed non-viable. In contrast, 2023 included an $8.4 million goodwill impairment.
• Other Income: Recorded $6.8 million in other income, net, including a $2.5 million gain on the revaluation of the Iluvien royalty and a $4.9 million gain from the write-off of contingent consideration liability.
• Interest Expense: Rose to $4.7 million from $1.8 million, largely due to the issuance of $32.9 million in 9.00% Senior Notes in late 2023.

Outlook, Risks, and Unusual Items

• Pharmaceutical Segment Divestiture: The Pharmaceutical Development segment (Enteris) is classified as held for sale following an Option and Asset Purchase Agreement with a strategic partner. The option must be exercised by January 1, 2026. Upon exercise, the Company will focus solely on the Finance Receivables segment.
• Credit Quality Risks: The Company faces significant credit risk in its portfolio. As of year-end, four finance receivables were on non-accrual status (Flowonix, Best ABT, Ideal Implant, and BIOLASE). BIOLASE filed for Chapter 11 bankruptcy in October 2024.
• Liquidity: The Company maintains a $60.0 million revolving credit facility with $35.6 million available. It also has $32.9 million in Senior Notes due 2027.
• Subsequent Events: In March 2025, the Company received approximately $17.3 million from the buyout of the Iluvien royalty and entered into an agreement to sell substantially all remaining performing royalty assets for approximately $34.0 million.
• Management Changes: The Company experienced leadership transitions in 2024, including the appointment of a new CFO in July 2024.

Investor Verification Checklist

• Portfolio Concentration: Verify the performance and repayment status of the top 5-10 borrowers, given the high concentration of assets in the life sciences sector.
• Impairment Methodology: Review the specific assumptions used for the $12.8 million provision for credit losses and the $5.8 million intangible asset impairment.
• Divestiture Timeline: Monitor the status of the Enteris asset sale option and the potential impact on future revenue streams if the transaction closes.
• Debt Covenants: Confirm continued compliance with the $5.0 million liquidity covenant and interest coverage ratios under the revolving credit facility.
• Subsequent Royalty Sale: Track the closing of the $34.0 million royalty portfolio sale to Soleus Capital announced in March 2025.